Zentalis Pharmaceuticals, Inc. ZNTL
1.78 USD -0.07 (-3.78%)
At closeNov 3, 2026, 4:01 PM EST
1.78 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
1.75 Day range 1.96
1.21 52-week range 6.95
- YTD
- +31.85%
- 1 year
- +23.61%
Analyst view
Consensus: buy
Buy
Price target (mean) 9.50 +433.7% upside
Now 1.78
- Target (low)
- 4.00
- Target (mean)
- 9.50
- Target (high)
- 20.00
Ratings (0m) 11 5 buy · 6 hold · 0 sell
- Strong buy1
- Buy4
- Hold6
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.78181 | -1.01 – -0.53 | -0.83 | +5.8% | 0 | 0.0% | 9 |
| Next quarter | -0.80 | -0.99 – -0.65 | 0.14 | -671.4% | 0 | -100.0% | 3 |
| Current year | -2.38 | -2.68 – -1.69 | -4.47 | +46.8% | 40.62M | 0.0% | 9 |
| Next year | -2.93 | -3.61 – -2.01 | -2.38 | -23.0% | 0 | -100.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Guggenheim | Maintained | Buy | Buy |
| Nov 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 16, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| Aug 12, 2024 | Wedbush | Upgrade | Underperform | Neutral |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 20, 2024 | UBS | Downgrade | Buy | Neutral |
| Jun 18, 2024 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Jun 18, 2024 | Stifel | Maintained | Buy | Buy |
| Jun 18, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 18, 2024 | Oppenheimer | Maintained | Outperform | Outperform |
| Jun 18, 2024 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| May 8, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 8, 2024 | Stifel | Maintained | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 28, 2024 | Wedbush | Maintained | Neutral | Neutral |
| Nov 8, 2023 | Wedbush | Downgrade | Outperform | Neutral |
| Nov 7, 2023 | Stifel | Maintained | Buy | Buy |
| Nov 7, 2023 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 7, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 10, 2023 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 10, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 10, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 7, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 7, 2023 | Stifel | Maintained | Buy | Buy |
| Jun 2, 2023 | Stifel | Maintained | Buy | Buy |
| May 29, 2023 | Stifel | Maintained | Buy | Buy |
| May 26, 2023 | Oppenheimer | Reiterated | Outperform | Outperform |
| May 26, 2023 | Wedbush | Maintained | Outperform | Outperform |
| May 26, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 23, 2023 | Stifel | Maintained | Buy | Buy |